VIDEO + ARTICLE:
Aducanumab for Alzheimer’s is showing encouraging results as Phase 3 trials roll out. See how this new immunotherapy is treating Alzheimer’s at Georgetown University.
This year, Biogen Inc. is executing two Phase 3 clinical trials for aducanumab in Alzheimer’s disease.
Continued below video…
Two global, placebo-controlled studies named ENGAGE and EMERGE are designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease (AD).
“Since the initial readout of our Phase 1b study, we have accelerated our aducanumab clinical program so that we can more fully characterize and confirm the benefit-risk profile of this investigational treatment for Alzheimer’s disease,” said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen. “We continue to work with our colleagues around the world to advance the study of aducanumab.”
Aducanumab (BIIB037) is an investigational compound being developed for the treatment of AD. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.
Aducanumab is thought to target aggregated forms of beta amyloid including soluble oligomers and insoluble fibrils deposited into the amyloid plaque in the brain of AD patients. Based on pre-clinical and interim Phase 1b data, treatment with aducanumab has been shown to reduce amyloid plaque levels.
RELATED VIDEO + ARTICLE:
Biogen Exceeds Expectations, Helps Clear Alzheimer’s Plaque
- Georgetown University
I'm glad they may have something promising but what about those of us with moderate to severe.
There are nutraceutical supplements,still under study, with dozens of well fundamented scientific research articles,about research in neuron cells cultures,in animal models and in human beings,that shows some good results as described in scientific articles.And it nutraceuticals,in a fast and easy way,looks to lowers not only the betamyloid and tau accumulation,but looks to works controlling what upstreams,leads to it accumulations of betamyloid and tau that are the biochemical,molecular, metabolical and brain energy disorders,that looks to be the triggers and looks to perpetuates that disorders.The problem is that such nutraceutical supplements that, maybe, could works as SUPPORT THERAPY in all stages of AD and in all stages of most types of others dementias,do not have none patent and are very very cheap.And substances that in some way works,but do not have patent and are cheap,are not attractive to some pharma companies…
This comment has been removed by the author.
We can find some information about failure wirh the substance aducanumab in the medical site Medpage Today,searching in the Google with the words: "Aducanumab 6-mg Dose Disappoints lack of cognitive improvements"
You might want to google Anavex Life Sciences. They also had two on-going trials, for Alzheimer's showing promising results. Lot of buzz around their 2-73 drug.
Will this drug also work for tau associated with CTE? My husband was diagnosed at 65 with early onset senile dementia attributed to multiple sports concussions and has been taking aricept for the last 5 years.